Selective estrogen receptor modulator
Raloxifene
Raloxifene is an oral selective estrogen receptor modulator. Its US label gives a plasma elimination half-life of 27.7 hours after oral dosing in healthy postmenopausal women and an absolute bioavailability of 2%.1
Raloxifene after one dose: 50% at ~28 h, 25% at 56 h, 12.5% at 84 h.
Drawn from the half-life in the app's model, ~28 h. The model's figures
- Compound
- Raloxifene
- Symbol
- RAL
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 14
- Checked
- Last reviewed . Sources are listed below.
Overview
Raloxifene hydrochloride is the active ingredient of Evista, and its US prescribing information, from Eli Lilly and Company, describes it as an estrogen agonist/antagonist given as a tablet by mouth.1 The label lists the treatment and prevention of osteoporosis in postmenopausal women and a reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of invasive breast cancer, and it states that Evista "is not indicated for the treatment of invasive breast cancer".1
For men, the label states: "There is no indication for the use of EVISTA in men. EVISTA has not been adequately studied in men and its use is not recommended".1 The largest trials described below enrolled postmenopausal women: 7,705 in MORE, 19,747 in STAR and 10,101 in RUTH.2,3,4
How it works
Sources in this part
The label states: "Raloxifene appears to act as an estrogen agonist in bone".1 It reports that raloxifene "decreases bone resorption and bone turnover, increases bone mineral density (BMD) and decreases fracture incidence", and that preclinical data "demonstrate that raloxifene is an estrogen antagonist in uterine and breast tissues".1
Birzniece and colleagues, Journal of Clinical Endocrinology and Metabolism, 2010, give as background that raloxifene "is used for therapy of osteoporosis in both sexes" and that its "neuroendocrine effects in men are poorly understood", while the US label states there is no indication for its use in men.5,1
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~28 h
- Bioavailability
- 2%
- Typical dose
- 60–120 mg/day
- Route
- Oral
- Time to peak
- ~4 h
The label gives a plasma elimination half-life of 27.7 hours after oral dosing, a mean of 32.5 hours on multiple dosing (its pharmacokinetic table is for healthy postmenopausal women), and an absolute oral bioavailability of 2%.1 The app's figure is a half-life of about 28 hours, and it lists the same 2% bioavailability and an oral route. The label says that raloxifene "undergoes extensive first-pass metabolism to the glucuronide conjugates", that no other metabolites have been detected, "providing strong evidence that raloxifene is not metabolized by cytochrome P450 pathways", and that it is "primarily excreted in feces".1
| Parameter | App's figure | Source figure |
|---|---|---|
| Half-life | ~28 h | Label, healthy postmenopausal women: 27.7 h after a single oral dose (observed range 10.7 to 273 h) and a mean of 32.5 h on multiple dosing (range 15.8 to 86.6 h)1. Lee and colleagues, 120 mg single dose with cholecalciferol 1,600 IU, 46 healthy men, mean ± SD: 33.90 ± 58.85 h (fixed-dose combination) and 26.87 ± 17.41 h (separate tablets)6 |
| Bioavailability | 2% | Label: absolute bioavailability 2%, with about 60% of an oral dose absorbed1 |
| Time to peak | ~4 h | Label: no figure given. Lee and colleagues: median 10.0 h (range 1.0 to 48.0) for the fixed-dose combination and 7.0 h (1.0 to 24.0) for separate tablets1,6 |
| Route | Oral | Label: tablet taken orally once daily1 |
Lee and colleagues, Translational and Clinical Pharmacology, 2022, gave 46 healthy Korean male volunteers a single oral 120 mg dose of raloxifene, as a fixed-dose combination with cholecalciferol or as separate tablets, after an overnight fast, in a two-way crossover with a 14-day washout.6 The study was sponsored by Alvogen Korea Co. Ltd., one author is an employee of that company, and the authors state that "The sponsor did not participate in the execution of the study or analysis of the data".6 The authors write that "The subjects who participated in this study were all healthy and young".6
The chart below is an illustration from the app's half-life of about 28 hours and time to peak of about 4 hours; the once-daily interval is the one the label's dosing statement and the large trials describe.1,2,3,4
Level over 1 weeks
Level, as a share of the peak after one 60 mg dose
As studied: every day1.
An illustration from a pharmacokinetic model using a half-life of 28 hours. It is not a measured level or a suggested dose.
Human studies
The trials with the most participants are in postmenopausal women: MORE, its CORE follow-up, STAR and RUTH.2,7,3,4
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Ettinger and colleagues, JAMA, 1999 (MORE)2 | Multicenter, randomized, blinded, placebo-controlled | 7,705 postmenopausal women aged 31 to 80 with osteoporosis (6,828 with evaluable radiographs) | 60 or 120 mg/d vs placebo, up to 36 months; all received calcium and cholecalciferol | New vertebral fracture in 10.1% on placebo, 6.6% on 60 mg and 5.4% on 120 mg (RR 0.7, 95% CI 0.5-0.8 and RR 0.5, 0.4-0.7); nonvertebral fracture RR 0.9 (0.8-1.1) for both doses combined, not significant; venous thromboembolism RR 3.1 (1.5-6.2)2 |
| Vogel and colleagues, JAMA, 2006 (STAR)3 | Prospective, double-blind, randomized, vs tamoxifen | 19,747 postmenopausal women at increased breast cancer risk, mean age 58.5 | Raloxifene 60 mg/d vs tamoxifen 20 mg/d, 5 years | Raloxifene vs tamoxifen. Initial analysis: invasive breast cancer 168 vs 163 cases, RR 1.02 (0.82-1.28); noninvasive 80 vs 57, RR 1.40 (0.98-2.00); thromboembolic events RR 0.70 (0.54-0.91); cataracts RR 0.79 (0.68-0.92); deaths 96 vs 1013. Update at median follow-up of 81 months: invasive breast cancer 310 vs 247, RR 1.24 (1.05-1.47)11 |
| Barrett-Connor and colleagues, NEJM, 2006 (RUTH)4 | Randomized, placebo-controlled | 10,101 postmenopausal women, mean age 67.5, with coronary heart disease or multiple risk factors | Raloxifene 60 mg daily vs placebo, median 5.6 years | Coronary events 533 vs 553 (HR 0.95, 0.84 to 1.07); invasive breast cancer 40 vs 70 (HR 0.56, 0.38 to 0.83); fatal stroke 59 vs 39 (HR 1.49, 1.00 to 2.24); venous thromboembolism 103 vs 71 (HR 1.44, 1.06 to 1.95)4 |
| Lawrence and colleagues, J Pediatr, 20048 | Retrospective chart review | 38 consecutive patients with persistent pubertal gynecomastia, mean age of treated subjects 14.6 years | 3- to 9-month course of tamoxifen or raloxifene, or reassurance alone | Mean breast nodule reduction 2.5 cm (95% CI 1.7, 3.3) with raloxifene and 2.1 cm with tamoxifen; greater than 50% decrease in 86% with raloxifene and 41% with tamoxifen; no side effects seen8 |
| Birzniece and colleagues, J Clin Endocrinol Metab, 20105 | Randomized, open-label crossover | 10 healthy men | Raloxifene 60 and 120 mg/d and tamoxifen 10 and 20 mg/d, 2-week sequential treatment, 2-week washout | Raloxifene did not significantly reduce IGF-I; LH, FSH and testosterone rose significantly (testosterone +25%, LH +30% with raloxifene vs +40% and +70% with tamoxifen)5 |
| Duschek and colleagues, Eur J Endocrinol, 20049 | Double-blind, placebo-controlled | 30 healthy men aged 60 to 70 (15 per group) | Raloxifene 120 mg/day or placebo, 3 months | LH +29%, FSH +21%, total testosterone +20%, free testosterone +16%, estradiol +21%, SHBG +7%, total PSA +17%; no side effects reported9 |
Deeper analysis: MORE
Ettinger and colleagues, for the MORE Investigators, Division of Research, Kaiser Permanente, reported MORE in JAMA in 1999.2 It was a multicenter, randomized, blinded, placebo-controlled trial of 7,705 women aged 31 to 80 years in 25 countries, postmenopausal for at least 2 years and meeting World Health Organization criteria for osteoporosis, with up to 36 months of follow-up for primary efficacy measurements.2
Of 6,828 women with evaluable radiographs, 503 (7.4%) had at least 1 new vertebral fracture, and the risk was reduced in both raloxifene groups.2 Nonvertebral fracture risk did not differ significantly from placebo, bone mineral density was higher than on placebo by 2.1% (60 mg) and 2.4% (120 mg) in the femoral neck and by 2.6% and 2.7% in the spine, and the authors note increased venous thromboembolism (RR 3.1, 95% CI 1.5-6.2) alongside a lower incidence of breast cancer.2 The authors conclude that "In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture".2
The PubMed record for MORE lists its type as research support, non-US government, and names no funder, no trial sponsor, no author ties to a company and no limitations of its own.2
In CORE, Martino and colleagues of the Cancer Institute Medical Group reported that the reduction in invasive breast cancer incidence continued beyond 4 years of raloxifene treatment, with the increased thromboembolism risk seen in MORE persisting over the 8 years of both trials, and the PubMed record names no funder.7
Deeper analysis: STAR
Vogel and colleagues of the National Surgical Adjuvant Breast and Bowel Project (NSABP) reported STAR in JAMA in 2006.3 It randomly assigned 19,747 postmenopausal women of mean age 58.5 years with increased 5-year breast cancer risk to tamoxifen 20 mg/d or raloxifene 60 mg/d for 5 years.3 Invasive breast cancer occurred in 163 women on tamoxifen and 168 on raloxifene (RR 1.02, 95% CI 0.82-1.28), noninvasive breast cancer in 57 and 80 (RR 1.40, 0.98-2.00), and uterine cancer in 36 and 23 (RR 0.62, 0.35-1.08).3 The authors concluded that "Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer" with a lower risk of thromboembolic events and cataracts, and "a nonstatistically significant higher risk of noninvasive breast cancer".3
The PubMed record lists National Cancer Institute grants and names no company funder, and the registry entry names the NSABP Foundation as lead sponsor with the National Cancer Institute, Eli Lilly and Company and AstraZeneca as collaborators.3,10 The PubMed record states no author ties to a sponsor and no limitations of its own.3
In the update at a median follow-up of 81 months, invasive breast cancer was higher on raloxifene (310 cases vs 247, RR 1.24, 95% CI 1.05-1.47), noninvasive disease was 137 vs 111 cases (RR 1.22, 0.95-1.59), invasive uterine cancer was lower (RR 0.55, 0.36-0.83) and thromboembolic events were lower (RR 0.75, 0.60-0.93).11 The authors write that raloxifene "retained 76% of the effectiveness of tamoxifen in preventing invasive disease", that the option of crossing over to raloxifene after unblinding, chosen by 879 women (9%), "is unlikely to fully explain our updated findings", and that "Raloxifene may simply be less potent than is tamoxifen".11 The update states funding from National Cancer Institute grants and carries no statement of author ties to a company.11
Deeper analysis: RUTH
Barrett-Connor and colleagues, New England Journal of Medicine, 2006, randomly assigned 10,101 postmenopausal women with coronary heart disease or multiple risk factors for it to raloxifene 60 mg daily or placebo for a median of 5.6 years, with coronary events and invasive breast cancer as the two primary outcomes.4 Raloxifene had "no significant effect on the risk of primary coronary events" (533 vs 553 events), reduced invasive breast cancer (40 vs 70 events, HR 0.56, 95% CI 0.38 to 0.83) and clinical vertebral fractures (64 vs 97 events, HR 0.65, 0.47 to 0.89), and was associated with fatal stroke (59 vs 39, HR 1.49) and venous thromboembolism (103 vs 71, HR 1.44).4 There was no significant difference in deaths from any cause or in total stroke.4
The registry lists Eli Lilly and Company as lead sponsor, and the PubMed record states no author ties and no limitations of its own.12,4
Deeper analysis: raloxifene in males
Lawrence and colleagues, University of Ottawa, reported in the Journal of Pediatrics in 2004 a retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia at a pediatric endocrinology clinic, of whom some received reassurance alone and others a 3- to 9-month course of tamoxifen or raloxifene.8 The mean age of treated subjects was 14.6 years and gynecomastia had lasted a mean of 28.3 months; some improvement was seen in 86% of patients on tamoxifen and 91% on raloxifene, and a decrease of more than 50% in 86% on raloxifene and 41% on tamoxifen.8 The authors state that "Further study is required to determine that this is truly a treatment effect".8 The PubMed record names no funder and gives no dose or per-group counts.8
Birzniece and colleagues of the Garvan Institute of Medical Research and St. Vincent's Hospital, Sydney, found in 10 healthy men that tamoxifen, but not raloxifene, significantly reduced IGF-I (by 25±6%) and raised SHBG (by 20±7%) at the higher dose, while both drugs significantly raised LH, FSH and testosterone and there was a nonstatistically significant trend toward a reduced GH response to arginine with both.5 They conclude that raloxifene "perturbs the GH and gonadal axes to a lesser degree than tamoxifen", and the record lists the study as research support, non-US government, with no named funder, no author ties and no limitations stated.5
Duschek and colleagues of VU University Medical Centre, Amsterdam, gave 30 healthy men aged 60 to 70 raloxifene 120 mg/day (n=15) or placebo (n=15) for 3 months, and total cholesterol fell from 5.7 to 5.5 mmol/l (P=0.03) while HDL cholesterol showed a trend to decrease.9 They conclude: "Overall, there were no clear beneficial effects of administration of raloxifene to ageing men in this preliminary investigation".9 The record names no funder and no author ties.9
Smith and colleagues of Massachusetts General Hospital randomized 48 men with nonmetastatic prostate cancer on a GnRH agonist to raloxifene 60 mg/d or none for 12 months, and total hip bone density rose 1.1% on raloxifene and fell 2.6% without it (P<0.001), while the lumbar spine difference was 1.0% vs -1.0% (P=0.07), with similar between-group differences in the femoral neck (P=0.06) and trochanter (P<0.001).13 The study was open-label, and the record lists National Institutes of Health grants (NIDDK K24 DK02759 and NCRR M01-RR-01066) and no limitations of its own.13
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Label, postmenopausal women1 | 60 mg tablet | Once daily | Optimum duration not known for the breast cancer indications |
| MORE2 | 60 or 120 mg | Daily (mg/d) | Up to 36 months |
| STAR3 | 60 mg | Daily (mg/d) | 5 years |
| Birzniece, 10 healthy men5 | 60 and 120 mg | Daily (mg/d) | 2-week sequential treatment |
| Duschek, 30 healthy men9 | 120 mg | Daily (mg/day) | 3 months |
| Lee, 46 healthy men6 | 120 mg | Single dose | Single dose per period, 14-day washout |
| Lawrence, pubertal gynecomastia8 | Not stated in the record | Not stated | 3- to 9-month course |
Side effects reported
The label carries a boxed warning titled "INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE", stating that increased risk of deep vein thrombosis and pulmonary embolism has been reported and that increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events.1 It reports 26 women with venous thromboembolism on raloxifene against 11 on placebo in the osteoporosis treatment trial (hazard ratio 2.4, 95% CI 1.2 to 4.5, against RR 3.1, 95% CI 1.5-6.2 in the MORE journal report2), and in RUTH 59 (1.2%) deaths from stroke against 39 (0.8%) on placebo, with no statistically significant difference in the incidence of stroke (249 [4.9%] vs 224 [4.4%]).1
Adverse reactions the label lists as more than 2% and more common than with placebo are hot flashes, leg cramps, peripheral edema, flu syndrome, arthralgia and sweating.1 The label's Table 1 gives hot flashes in 9.7% on raloxifene against 6.4% on placebo in the osteoporosis treatment trial and 24.6% against 18.3% in the prevention trials, and leg cramps in 7.0% against 3.7% and 5.9% against 1.9%.1 In MORE, hot flashes occurred in about one in 10 patients, were most commonly reported in the first 6 months and were not different from placebo thereafter, and leg cramps occurred in about one in 14 patients.1 In the prevention trials, hot flashes occurred in about one in four patients on raloxifene against about one in six on placebo.1 Therapy was discontinued because of an adverse reaction in 10.9% of raloxifene-treated and 8.8% of placebo-treated women in MORE and in 11.4% and 12.2% in the prevention trials.1
In STAR, raloxifene had fewer thromboembolic events (RR 0.70, 95% CI 0.54-0.91) and fewer cataracts (RR 0.79, 0.68-0.92) than tamoxifen, and the total number of deaths did not differ (101 on tamoxifen, 96 on raloxifene).3 In the 46-man pharmacokinetic study, 3 subjects (6.5%) reported 6 treatment-emergent adverse events, one (hypercalciuria) considered possibly related to the study drug, with no serious adverse events.6
Bloodwork and markers
Sources in this part
In 30 healthy men aged 60 to 70, raloxifene 120 mg/day for 3 months raised LH by 29%, FSH by 21%, total testosterone by 20%, free testosterone by 16% and 17 beta-estradiol by 21%, with SHBG up 7% and total PSA up 17% and no significant change in free PSA or the free-to-total PSA ratio.9 In 10 healthy men, raloxifene raised LH, FSH and testosterone and, unlike tamoxifen, did not significantly change IGF-I.5
The label reports that raloxifene produced "consistent, statistically significant suppression of bone resorption and bone formation" markers in women, and small decreases in serum total calcium, inorganic phosphate, total protein and albumin, and a slight decrease in platelet count.1
Regulatory and anti-doping status
Sources in this part
The US label shows an initial US approval of 1997.1 It states that safety and effectiveness in pediatric patients have not been established, and that the pharmacokinetics of raloxifene has not been evaluated in a pediatric population.1 It lists active or past venous thromboembolism and pregnancy as contraindications.1
The WADA Prohibited List 2026 names raloxifene in class S4.2, anti-estrogenic substances (anti-estrogens and selective estrogen receptor modulators), under hormone and metabolic modulators, which is prohibited at all times, in and out of competition.14 The list states that prohibited substances in classes S4.1 and S4.2 are Specified Substances.14
Storage and handling
Sources in this part
The Evista label lists storage at controlled room temperature, 20° to 25°C (68° to 77°F).1
What is not known
Sources in this part
The label gives no time to peak figure, so the app's 4 hours has no label figure beside it.1 It states that raloxifene has not been adequately studied in men, and that safety and effectiveness in pediatric patients have not been established.1 Birzniece and colleagues write that raloxifene's "neuroendocrine effects in men are poorly understood".5 A search of PubMed on 15 November 2026 for raloxifene together with gynecomastia returned 5 records, one of which is the Lawrence chart review described above.8
Frequently asked questions
What is the half-life of raloxifene?
The US label gives a plasma elimination half-life of 27.7 hours after oral dosing and a mean of 32.5 hours on multiple dosing, in healthy postmenopausal women.1 The app's figure is about 28 hours, and in 46 healthy men given a single 120 mg dose with cholecalciferol 1,600 IU the mean ± SD half-life was 33.90 ± 58.85 hours for the fixed-dose combination and 26.87 ± 17.41 hours for separate tablets.6
What is the bioavailability of raloxifene?
What is the time to peak of raloxifene?
Is raloxifene banned by WADA?
What is raloxifene?
What are the side effects of raloxifene?
The label lists hot flashes, leg cramps, peripheral edema, flu syndrome, arthralgia and sweating as adverse reactions above 2% and more common than with placebo.1 In its osteoporosis treatment trial the label's Table 1 gives hot flashes in 9.7% on raloxifene against 6.4% on placebo and leg cramps in 7.0% against 3.7%.1 Its boxed warning covers an increased risk of venous thromboembolism and of death from stroke in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events, where fatal stroke occurred in 59 women on raloxifene and 39 on placebo (HR 1.49, 95% CI 1.00 to 2.24).1,4
Does raloxifene raise testosterone in men?
In two studies in healthy men, raloxifene raised testosterone: by 20% in 30 men aged 60 to 70 on 120 mg/day for 3 months, and significantly in a 10-man crossover with 2-week sequential treatment at 60 and 120 mg/d.9,5 Free testosterone rose by 16%, SHBG by 7% and total PSA by 17% in the larger study, which the authors called a preliminary investigation.9
How does raloxifene compare with tamoxifen?
In STAR, 19,747 postmenopausal women had invasive breast cancer in 168 on raloxifene and 163 on tamoxifen (RR 1.02), and at 81 months the update reported 310 vs 247 cases (RR 1.24, 95% CI 1.05-1.47).3,11 In 10 healthy men, tamoxifen but not raloxifene significantly reduced IGF-I, and in a retrospective chart review of 38 patients with pubertal gynecomastia a decrease of more than 50% occurred in 86% of those given raloxifene and 41% of those given tamoxifen, with some improvement in 91% and 86%, and the authors state that "Further study is required to determine that this is truly a treatment effect".5,8
Has raloxifene been studied for gynecomastia?
Lawrence and colleagues reviewed charts of 38 consecutive patients with persistent pubertal gynecomastia, and the mean reduction in breast nodule diameter was 2.5 cm with raloxifene (95% CI 1.7, 3.3) and 2.1 cm with tamoxifen.8 The authors wrote that "Further study is required to determine that this is truly a treatment effect".8
Guides, tools and comparisons
- Raloxifene dosage for gynoA guide that answers a question on this compound.
- Nolvadex vs raloxifeneA side-by-side with another compound.
- Previous in Post-cycle and ancillaries: PramipexoleThe compound before this one in the class.
- Next in Post-cycle and ancillaries: RosuvastatinThe compound after this one in the class.
References
- Eli Lilly and Company. EVISTA (raloxifene hydrochloride) tablets, US prescribing information. DailyMed, label text dated March 2023. DailyMed label
- Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999. PMID 10517716
- Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006. PMID 16754727
- Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006. PMID 16837676
- Birzniece V, Sata A, Sutanto S, Ho KK. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. J Clin Endocrinol Metab 2010. PMID 20843951
- Lee HW, Kang WY, Gwon MR, et al. A randomized, open-label, single-dose, two-way crossover study to assess the pharmacokinetics between two tablets of fixed-dose combination formulation with raloxifene and cholecalciferol and concomitant administration of each agents in healthy male volunteers. Transl Clin Pharmacol 2022. PMC9532856
- Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004. PMID 15572757
- Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 2004. PMID 15238910
- Duschek EJ, Gooren LJ, Netelenbos C. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol 2004. PMID 15080785
- ClinicalTrials.gov. Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women. NCT00003906. First submitted 1999. NCT00003906
- Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res 2010. PMC2935331
- ClinicalTrials.gov. Raloxifene Use for The Heart (RUTH). NCT00190593. First submitted 2005. NCT00190593
- Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004. PMID 15292315
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA Prohibited List 2026